Evidence map›Paper›PMID 20937629›Full record

ArticleNucleic acids research2011

Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations.

Coren A Milbury, Jin Li, G Mike Makrigiorgos

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Nucleic acids research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 107 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Coren A MilburyDepartment of Radiation Oncology, Division of Medical Physics and Biophysics, Dana Farber-Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Jin Li
G Mike Makrigiorgos
Brigham and Women's Hospital · USDana-Farber Brigham Cancer Center · US

Funding

RADIATION BIOLOGY TRAINING PROGRAMT32CA009078 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI D'ANDREA, ALAN D. · 1985 to 2009
$4.6M
Technology for sensitive and reliable mutational profiling in pancreatic cancerR21CA138280 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. MIKE · 2009 to 2011
$751k
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATIONR33CA111994 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. MIKE · 2007 to 2008
$656k
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATIONR21CA111994 · NCI · DANA-FARBER CANCER INSTITUTE · PI MAKRIGIORGOS, G. MIKE · 2005 to 2006
$290k
NCI NIH HHS CA-111994NCI NIH HHS CA-138280NCI NIH HHS R21 CA111994NCI NIH HHS R21 CA138280NCI NIH HHS R33 CA111994NCI NIH HHS T32-CA009078
6 · The paper itself

Abstract

Identifying low-abundance mutations within wild-type DNA is important in several fields of medicine, including cancer, prenatal diagnosis and infectious diseases. However, utilizing the clinical and diagnostic potential of rare mutations is limited by sensitivity of the molecular techniques employed, especially when the type and position of mutations are unknown. We have developed a novel platform that incorporates a synthetic reference sequence within a polymerase chain reaction (PCR) reaction, designed to enhance amplification of unknown mutant sequences during COLD-PCR (CO-amplification at Lower Denaturation temperature). This new platform enables an Improved and Complete Enrichment (ice-COLD-PCR) for all mutation types and eliminates shortcomings of previous formats of COLD-PCR. We evaluated ice-COLD-PCR enrichment in regions of TP53 in serially diluted mutant and wild-type DNA mixtures. Conventional-PCR, COLD-PCR and ice-COLD-PCR amplicons were run in parallel and sequenced to determine final mutation abundance for a range of mutations representing all possible single base changes. Amplification by ice-COLD-PCR enriched all mutation types and allowed identification of mutation abundances down to 1%, and 0.1% by Sanger sequencing or pyrosequencing, respectively, surpassing the capabilities of other forms of PCR. Ice-COLD-PCR will help elucidate the clinical significance of low-abundance mutations and our understanding of cancer origin, evolution, recurrence-risk and treatment diagnostics.

Indexed as

Base SequenceCell Line, TumorDNA Mutational AnalysisDNA, NeoplasmHumansMaleMutationNucleic Acid HybridizationPolymerase Chain ReactionReference StandardsTemperatureDNA, Neoplasm

Identifiers

PMID20937629
PMCPMC3017621
OpenAlexW2068262084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.